Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer

被引：0
|
作者：
de la Calle, Claire Marie
Chang, Albert
Rashid, Ghezal
Wong, Anthony C.
Choi, Alice
Feng, Felix Y.
Gottschalk, Alexander R.
Menzel, Paul Lawrence
Carroll, Peter
Hao Gia Nguyen
机构：
[1] UCSF, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[4] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] CPMC, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
323
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Koshkin, Vadim S.
    Mir, Maria C.
    Barata, Pedro
    Gul, Anita
    Gupta, Ruby
    Stephenson, Andrew J.
    Kaouk, Jihad
    Berglund, Ryan
    Magi-Galluzzi, Cristina
    Klein, Eric A.
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 559 - 566
  • [22] PHASE II STUDY OF VINORELBINE AND ESTRAMUSTINE IN COMBINATION WITH CONFORMATIONAL RADIOTHERAPY FOR PATIENTS WITH HIGH-RISK PROSTATE CANCER
    Carles, Joan
    Nogue, Miguel
    Sole, Josep M.
    Foro, Palmira
    Domenech, Montserrat
    Suarez, Marta
    Gallardo, Enrique
    Garcia, Dario
    Ferrer, Ferran
    Gelabert-Mas, Antoni
    Gayo, Javier
    Fabregat, Xavier
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (04): : 1085 - 1091
  • [23] Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial
    Nagar, Himanshu
    Formenti, Silvia
    Scherr, Douglas
    Hu, Jim C.
    Schlegel, Peter
    Kang, Josephine
    Robinson, Brian D.
    Khani, Francesca
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Margolis, Daniel
    Barbieri, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
    Aas, Kirsti
    Berge, Viktor
    Myklebust, Tor Age
    Fossa, Sophie Dorothea
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 26 : 55 - 63
  • [25] Disseminated Tumor Cells in Bone Marrow Following Definitive Radiotherapy for Intermediate or High-Risk Prostate Cancer
    Berg, Arne
    Bruland, Oyvind S.
    Fossa, Sophie D.
    Nesland, Jahn M.
    Berner, Aasmund
    Schirmer, Cecilie
    Lilleby, Wolfgang
    PROSTATE, 2008, 68 (15): : 1607 - 1614
  • [26] Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer
    Blanchard, P.
    Faivre, L.
    Lesaunier, F.
    Salem, N.
    Mesgouez-Nebout, N.
    Deniaud-Alexandre, E.
    Ferrero, J. M.
    Houede, N.
    Habibian, M.
    Fizazi, K.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S22 - S22
  • [27] Pelvic proton radiotherapy for high-risk prostate cancer
    Chera, B. S.
    Vargas, C.
    Flampouri, S.
    Morris, C. G.
    Yeung, D.
    Olivier, K.
    Duvvuri, S.
    Li, Z.
    Mendenhall, N. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S326 - S326
  • [28] Use and timing of radiotherapy in high-risk prostate cancer
    Ward, JF
    Blute, ML
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (23): : 2817 - 2817
  • [29] Radiotherapy after prostatectomy in high-risk prostate cancer
    Roviello, G.
    Villari, D.
    Nesi, G.
    Detti, B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (11): : 2139 - 2140
  • [30] Is surgery superior to radiotherapy for high-risk prostate cancer?
    Eastham, James A.
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 438 - 438
12345